Together, these results are in line with neoadjuvant studies demonstrating that improved responses are associated with increased CD8 T cell proliferation and tumor infiltration (Fig. 2), which were achieved via concurrent drug modulation of immune checkpoint pathways in the TME and LNs. Here, CD8A is linked to neoplasm.